The product page is the least available lever
Promotional content is restricted to approved indications, must carry required safety information, and in several markets cannot be directed at the public at all. That removes the page a marketing team would normally optimise and shifts the opportunity entirely to unbranded and scientific content.
Disease-state education is where the volume actually is. Patients and clinicians search conditions, symptoms and treatment options far more than brand names, and unbranded educational content can serve those queries within the rules — provided it stays genuinely educational rather than promotional in disguise.
The scientific literature is the other durable asset. Publications, trial results and congress material are cited by clinicians, journalists and increasingly by assistants answering treatment questions, and that citation base compounds in a way promotional content is not permitted to.
How clinicians and patients search
Healthcare professionals search mechanism, evidence, dosing, interactions and comparative efficacy, and they expect primary sources. Content that summarises without citing is discounted immediately by this audience, while well-referenced material earns durable citation from both practitioners and the systems that answer their questions.
Patients and carers search symptoms, prognosis, side effects and practical daily-life questions, usually before any brand is involved. Unbranded educational content serves them within the rules and reaches them far earlier than product material could.
Trial information is searched by both audiences and is chronically under-served. Clear, plain-language trial pages with eligibility criteria and locations meet genuine demand and satisfy transparency commitments simultaneously.
Promotion rules, adverse events and market variation
Direct-to-consumer promotion of prescription products is prohibited in most markets and permitted in a few, which makes a single global site untenable. Market gating, geo-appropriate content and clear separation between audiences are structural requirements rather than optimisations, and they interact awkwardly with how search engines want to serve content.
Adverse event reporting obligations attach to any channel where a patient might describe a reaction. Comment sections, contact forms and social presence all create a monitoring duty with defined timelines, which is why many pharmaceutical sites disable interaction entirely rather than staff the obligation.
Off-label discussion carries serious consequences, and it can arrive indirectly. Content that ranks for an unapproved use, or an assistant summarising your material alongside off-label information, creates exposure that the original page did not intend. Monitoring what you rank for matters as much as choosing what to publish.
Where the weight sits
GEO carries most of the return in this sector. Clinicians and patients increasingly ask assistants about conditions and treatments, and those answers draw on published literature and educational content — the two areas where a pharmaceutical company can legitimately compete.
What goes wrong here
- Serving one global site across markets with incompatible promotion rules
- Opening comment or interaction channels without staffing adverse event monitoring
- Publishing unbranded education that reads as promotion, which fails both tests
- Ignoring trial transparency pages, which meet real demand and existing commitments
- Failing to monitor which queries you rank for, including off-label ones
Services that apply
- International SEO
- Market gating is a regulatory requirement here, not an optimisation choice
- Topical Authority
- Disease-state education is where the searchable volume legitimately sits
- Entity Optimization
- Establishes compounds, indications and organisations unambiguously across sources
- Original Research
- Publications and trial data are the citation base assistants draw on
- AEO Monitoring
- Surfaces what you rank for, including queries you did not intend to serve
Questions
Can we do SEO at all under promotional restrictions?
Yes, but not on product pages in most markets. The available ground is disease-state education, scientific publication and trial transparency, which is also where the search volume actually sits.
How do we handle different rules across markets?
Separate market sites with appropriate gating and hreflang, rather than one site with disclaimers. The rules differ too fundamentally for a single version to be compliant everywhere.
Does opening a comment section create obligations?
Yes. Any channel where a patient could describe a reaction creates an adverse event monitoring duty with defined reporting timelines. Most companies close interaction rather than staff it, which is a legitimate choice.
Work in Pharma and biotech?
Thirty minutes with a senior strategist who has worked in this sector. We pull your live visibility while we talk and tell you which constraint is actually binding. Book a discovery call →